Clinical trial

Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

NCT05597202

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Semaglutide, 2.0 mg/mL Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE4

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2023-01-01

PhasePHASE4

Conditions

Type 2 Diabetesverified · MONDO: type 2 diabetes mellitus

Interventions

Semaglutide, 2.0 mg/mLDRUG

Sponsors & collaborators

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)lead sponsor

Dutch Heart Foundationcollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05597202 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.